gemcitabine + nedaplatin

Gemcitabine + nedaplatin is a combination chemotherapy regimen utilized as induction therapy in the treatment of nasopharyngeal carcinoma. Gemcitabine is a pyrimidine nucleoside analog that, once phosphorylated, inhibits ribonucleotide reductase and competes with dCTP for incorporation into DNA, leading to chain termination. Nedaplatin is a second-generation platinum complex that forms reactive intermediates which create inter- and intra-strand DNA cross-links, inhibiting DNA replication and transcription. In the specific context of the Shanghai Proton and Heavy Ion Center, this regimen is being evaluated in a Phase 2 trial (NCT04214431) as a component of a salvage treatment strategy that includes carbon-ion radiotherapy and the PD-1 inhibitor camrelizumab for patients with locally recurrent nasopharyngeal carcinoma.

Other names

gemcitabine plus nedaplatinGP regimen